ArticleExperimental eye research2025
Loss of monocyte chemoattractant protein-1 reduced monocyte recruitment and preserved retinal ganglion cells in a mouse model of hypertensive glaucoma.
Article in Experimental eye research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dual immune armies in glaucoma: microglia and monocyte-derived macrophages.Frontiers in immunology · 2026Review
- Current Challenges of Managing Fibrosis Post Glaucoma Surgery and Future Perspectives.Journal of clinical medicine · 2025Review
- Evaluating the Optic Nerve Crush Model to Understand the Function of Microglia in Glaucoma Neuroprotection.Investigative ophthalmology & visual science · 2025Article
- The role of microglia in glaucoma - trigger and potential target.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Monocyte chemoattractant protein-1 (MCP-1)/CCL2, a potent chemokine for myeloid cells, has been associated with disease progression in glaucoma. We examined whether genetic knockout (KO) of MCP-1 affected RGC density and function, retinal myeloid cell density, and pro-inflammatory cytokine expression in the setting of microbead induced hypertensive glaucoma. Adult wildtype (WT) C57BL/6J or MCP-1 KO mice received bilateral injections of either magnetic microbeads to elevate intraocular pressure (IOP) or balanced salt solution (BSS) as normotensive controls. After 8 weeks, immunolabeling of retina flat mounts for RBPMS and Iba1 quantified RGC and myeloid soma density in the retina, respectively. Axon density was quantified in optic nerve thin sections, while in vitro multi-electrode array recordings characterized RGC function. Quantitative PCR assessed expression of pro-inflammatory cytokines C1q, IL-1α, and TNF-α in macrophage/microglia-enriched retinal cellular populations. Results demonstrated lower RGC soma and axon density, and higher myeloid cellular density, in bead vs. BSS-injected eyes of WT mice. In contrast, RGC soma and axon density, as well as myeloid cellular density did not differ between bead and BSS-injected eyes of MCP-1 KO mice. Aspects of RGC firing rates were also preserved in KO compared to WT mice after IOP elevation. Interestingly, expressions of C1q, IL-1α, and TNF-α, cytokines previously shown to be cytotoxic to RGCs, did not differ between WT and KO mice. In summary, genetic ablation of MCP-1 rescued RGCs and decreased myeloid density in the retina without altering pro-inflammatory cytokine expression, supporting a pathogenic role for monocyte recruitment in hypertensive glaucoma.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.